ClinicalTrials.Veeva

Find clinical trials for Heart Disease in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Heart Diseases
Coronary Artery Disease
Cardiovascular Diseases
Myocardial Ischemia
Heart Failure
Coronary Disease
Hypertension

Heart Disease trials near Barcelona, CT, ESP:

Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial

tomography (OCT) findings indicative of vulnerable plaque, in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease...

Enrolling
Ischemic Heart Disease
Coronary Artery Disease
Other: FFR>0.80+ OCT with findings indicative of vulnerable plaque
Fundación EPIC

Barcelona, Spain and 41 other locations

Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation (VANTAGE)

Evaluation of TAVR using the NAVITOR valve in a Global Investigation.

Enrolling
Symptomatic Severe Aortic Stenosis
Device: Navitor Transcatheter Aortic Valve and FlexNav Delivery System
Abbott
Abbott

Barcelona, Spain and 37 other locations

Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System (VIVA)

This is a prospective, single arm, multicenter study in an expanding cohort of 150 symptomatic patients with severe aortic stenosis who will be follo...

Enrolling
Symptomatic Aortic Stenosis
Device: Vienna Aortic Valve SE System
P+F Products + Features

Barcelona, Spain and 22 other locations

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL)

The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

Phase 3

Novo Nordisk
Novo Nordisk

Barcelona, Spain and 467 other locations

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF)

reduction of cardiovascular death (generally meaning death due to disease of the heart or blood vessels) and total Heart F...

Active, not recruiting
Heart Failure
Other: Placebo
Drug: Finerenone (BAY94-8862)

Phase 3

Bayer
Bayer

Barcelona, Spain and 663 other locations

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardio...

Enrolling
Cardiovascular Disease
Drug: Semaglutide
Drug: Cagrilintide

Phase 3

Novo Nordisk
Novo Nordisk

Barcelona, Spain and 521 other locations

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

Phase 3

Amgen
Amgen

Barcelona, Cataluña, Spain and 851 other locations

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients (TripleTRE)

TripleTRE investigates the effect of initial triple combination therapy (oral endothelin receptor antagonist (ERA) + oral phosphodiesterase tyüe-5 in...

Enrolling
Pulmonary Arterial Hypertension
Drug: Generic treprostinil sodium + Standard of Care (Double Oral)
Drug: Standard of Care - Double Oral

Phase 4

AOP Orphan

Barcelona, Spain and 18 other locations

Locations recently updated

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...

Enrolling
Chronic Kidney Disease
Cardiac Disease
Drug: Placebo
Drug: Ravulizumab

Phase 3

Alexion Pharmaceuticals
Alexion Pharmaceuticals

Barcelona, Spain and 173 other locations

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) ...

Enrolling
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
Allogeneic Hematopoietic Cell Transplant
Biological: tabelecleucel

Phase 3

Atara Biotherapeutics

Barcelona, Spain and 70 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems